Journal Article

Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle

Rader, Erik P., Saito, Fumiaki, Anderson, Mary E., Beltrán, Daniel, Inamori, Kei-ichiro, Matsumura, Kiichiro, Campbell, Kevin P., Turk, Rolf, Willer, Tobias, Peterson, Taylor A., Engle, Jeffrey, Prouty, Sally

2016

Overview

Dystroglycan (DG) is a highly expressed extracellular matrix receptor that is linked to the cytoskeleton in skeletal muscle. DG is critical for the function of skeletal muscle, and muscle with primary defects in the expression and/or function of DG throughout development has many pathological features and a severe muscular dystrophy phenotype. In addition, reduction in DG at the sarcolemma is a common feature inmuscle biopsies from patients with various types of muscular dystrophy. However, the consequence of disrupting DG in mature muscle is not known. Here, we investigated muscles of transgenic mice several months after genetic knockdown of DG at maturity. In our study, an increase in susceptibility to contraction-induced injury was the first pathological feature observed after the levels of DG at the sarcolemma were reduced. The contraction-induced injury was not accompanied by increased necrosis, excitation–contraction uncoupling, or fragility of the sarcolemma. Rather, disruption of the sarcomeric cytoskeleton was evident as reduced passive tension and decreased titin immunostaining. These results reveal a role for DG in maintaining the stability of the sarcomeric cytoskeleton during contraction and provide mechanistic insight into the cause of the reduction in strength that occurs in muscular dystrophy after lengthening contractions.

• Publisher: National Academy of Sciences
• Subject: Biological Sciences / Cytoskeleton / Dystrophy / Genotype & phenotype / Muscles / Muscular dystrophy / Musculoskeletal system / Physiology / Protein expression / Proteins